Source briefingOctober 13, 2026Health & Science

Evaluating the impact and cost-effectiveness of typhoid conjugate vaccine schedules across diverse settings: A multi-model comparison

Source briefing · A concise briefing based on one linked source. It is intentionally shorter than a full FreedomWitness Evidence Engine analysis.

What the source reports

by Catherine G. C. Wenger, Kyra H. Grantz, Tigist F. Menkir, Alina M. Muellenmeister, Zeaan Pithawala, Raymond Hutubessy, Vittal Mogasale, Alicia N.

M. Kraay, Nick Scott, Romesh G. Abeysuriya, Jason R. Andrews, Jillian Gauld, Nathan C. Lo, Virginia E. Pitzer Background Given emerging evidence on the waning of immunity from typhoid conjugate vaccines (TCV), the World Health Organization (WHO) commissioned a multi-model comparison to determine the optimal schedule in terms of health and economic impact to inform updated recommendations for TCV use…

Evidence note: At this stage FreedomWitness is presenting what this source reports. This briefing does not independently prove every underlying claim and should be read together with the original material.

Source & verification

Primary source: PLOS Medicine · October 13, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

EMA/PE/0000181364

What is established The European Medicines Agency (EMA) has granted a decision regarding a paediatric investigation plan (PIP) for vosoritide as of 8 August…

EMA/PE/0000228795

Evidence Dossier: EMA Paediatric Investigation Plan for Ambrisentan/Tadalafil What is established The European Medicines Agency (EMA) has officially adopted a paediatric investigation plan (PIP)…

EMA/PE/0000261344

Evidence Dossier: EMA Decision on Colchicine Paediatric Investigation Plan (PIP) What is established On 8 August 2025, the European Medicines Agency (EMA) granted a…